Jco precision oncology.

DOI: 10.1200/PO.18.00028 JCO Precision Oncology - published online October 19, 2018WebDOI: 10.1200/PO.21.00181 JCO Precision Oncology no. 6 (2022) e2100181. Published online March 9, 2022. PMID: 35263168. Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors Pashtoon M. Kasi, MD, MS 1. x. Pashtoon M. Kasi. Search for articles by …WebDOI: 10.1200/PO.23.00338 JCO Precision Oncology no. 7 (2023) e2300338. Published online December 1, 2023. Published online December 1, 2023. Homologous Recombination Deficiency Across Subtypes of …DOI: 10.1200/PO.22.00107 JCO Precision Oncology no. 6 (2022) e2200107. Published online August 17, 2022. PMID: 35977349. Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors Matthew Dankner, BSc 1, 2, 3. x. Matthew Dankner. Search for articles by this …Purpose A long natural history and a predominant osseous pattern of metastatic spread are impediments to the adoption of precision medicine in patients with prostate cancer. To establish the feasibility of clinical genomic profiling in this disease, we performed targeted deep sequencing of tumor and normal DNA from patients with …Web

DOI: 10.1200/PO.18.00247 JCO Precision Oncology - published online April 25, 2019 PMID: 32914012. Precision Oncology in Sarcomas: Divide and Conquer Roberto Carmagnani Pestana, MD 1. x. Roberto Carmagnani Pestana. Search for articles by this author ; Roman Groisberg, MD 1. x. Roman Groisberg ...

DOI: 10.1200/PO.17.00084 JCO Precision Oncology - published online October 3, 2017The actual frequency of NTRK fusions in thyroid cancer is not known, as some targeted exome sequencing can easily miss fusion event involving introns of certain genes. Studies on frequency of NTRK fusions from a single institution and from the TCGA found NTRK fusion in 10 of 451 (2.2%; four NTRK1 and six NTRK3 fusions) and 12 of …Web

DOI: 10.1200/JCO.21.02112 Journal of Clinical Oncology - published online before print January 25, 2022 PMID: ... Journal of Clinical Oncology JCO Oncology Practice JCO Global Oncology JCO Clinical Cancer Informatics JCO Precision Oncology. Publications. ASCO Educational Book ASCO Daily News ASCO Connection The ASCO …PURPOSE The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a phase II pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancer with genomic alterations known to be drug targets. Results in a cohort of patients with non–small-cell lung cancer (NSCLC) with CDKN2A alterations treated with palbociclib are ...PURPOSE Promising single-agent activity from sotorasib and adagrasib in KRASG12C-mutant tumors has provided clinical evidence of effective KRAS signaling inhibition. However, comprehensive analysis of KRAS-variant prevalence, genomic alterations, and the relationship between KRAS and immuno-oncology biomarkers is lacking. MATERIALS AND METHODS Retrospective analysis of deidentified records ...Lung cancer is the leading cause of cancer-related death worldwide. Non–small-cell lung cancer (NSCLC), which accounts for 85% of all lung cancer cases, 1 is a group of heterogeneous diseases driven by a spectrum of molecular alterations. Targeted therapies directed toward specific molecular alterations, such as a mutation in epidermal …

The actual frequency of NTRK fusions in thyroid cancer is not known, as some targeted exome sequencing can easily miss fusion event involving introns of certain genes. Studies on frequency of NTRK fusions from a single institution and from the TCGA found NTRK fusion in 10 of 451 (2.2%; four NTRK1 and six NTRK3 fusions) and 12 of …Web

An Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry. Le Tourneau et al. Published online: August 8, 2022.

DOI: 10.1200/PO.20.00495 JCO Precision Oncology no. 5 (2021) 1122-1132. Published online July 9, 2021. Clinical Outcomes of Molecular Tumor Boards: A Systematic Review Kara L. Larson, PhD …WebJCO PO is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other …Diagnosis & treatment of ercc3-mutant cancer US20210137850A1. Other Relationship: AnaNeo Therapeutics. Jinru Shia. Consulting or Advisory Role: PAIGE.AI. Zsofia K. Stadler. This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.This author is an Editor for JCO Precision Oncology. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Genome Medical, GI OnDemand. Consulting or Advisory Role: Invitae, Genome Medical, Promega, 23andMe, GI OnDemand. Huma Q. Rana. Research Funding: Ambry Genetics ...OncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic mutations and structural alterations present in patient tumors with the goal of supporting optimal treatment decisions.JCO PO is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer. Innovative and timely scientific and educational content provide a deeper ...JCO PO publishes controlled randomized clinical trials and other comparative studies in precision oncology. For randomized clinical trials and other comparative studies, authors should carefully follow the ICMJE and CONSORT statement guidelines. To produce consistent results, please refer to JCO PO 's CONSORT template.

DOI: 10.1200/PO.22.00024 JCO Precision Oncology no. 6 (2022) e2200024. Published online October 6, 2022. PMID: 36201714Jan 12, 2023 · PURPOSE With the growing number of available targeted therapeutics and molecular biomarkers, the optimal care of patients with cancer now depends on a comprehensive understanding of the rapidly evolving landscape of precision oncology, which can be challenging for oncologists to navigate alone. METHODS We developed and implemented a precision oncology decision support system, GI TARGET ... JCO Precision Oncology ( JCO PO) is a peer-reviewed, online-only journal publishing original research, reports, opinions, and reviews that advance the science and practice of …DOI: 10.1200/PO.20.00250 JCO Precision Oncology no. 5 (2021) 204-214. Published online January 14, 2021. Published online January 14, 2021. NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical OutcomeFeb 16, 2022 · The actual frequency of NTRK fusions in thyroid cancer is not known, as some targeted exome sequencing can easily miss fusion event involving introns of certain genes. Studies on frequency of NTRK fusions from a single institution and from the TCGA found NTRK fusion in 10 of 451 (2.2%; four NTRK1 and six NTRK3 fusions) and 12 of 498 (2.4%; five ...

DOI: 10.1200/PO.20.00429 JCO Precision Oncology no. 5 (2021) 1001-1012. Published online June 10, 2021. PMID: 34994626. Cancer Diagnoses Following Abnormal Noninvasive Prenatal Testing: A Case Series, Literature Review, and Proposed Management Model Eryn Dow, BSc, BMBS 1, 2. x. Eryn Dow. Search for articles by this …DOI: 10.1200/PO.21.00101 JCO Precision Oncology no. 5 (2021) 1166-1177. Published online July 21, 2021. Published online July 21, 2021. Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases

DOI: 10.1200/PO.20.00494 JCO Precision Oncology no. 5 (2021) 1325-1338. Published online August 25, 2021. Published online August 25, 2021. Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard TherapiesDec 1, 2023 · PURPOSE Immune checkpoint inhibitors (ICIs) are used for an increasing number of indications across various tumor types, as well as several tumor-agnostic indications in patients with advanced cancer. Although many patients benefit from ICI therapy, others do not, highlighting a need for better predictive biomarkers. Tumor mutational burden (TMB) reflects the global number of mutations within ... DOI: 10.1200/PO.21.00510 JCO Precision Oncology no. 6 (2022) e2100510. Published online June 8, 2022. PMID: 35675577. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures Kabir Mody, MD 1. x. Kabir Mody. Search for articles by this author; ...WebDOI: 10.1200/PO.21.00122 JCO Precision Oncology no. 5 (2021) 1354-1376. Published online August 25, 2021. Published online August 25, 2021. Characterization of Non–Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment PatternsThis author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Employment: Foundation Medicine. Stock and Other Ownership Interests: Roche. Hanna Tukachinsky. Employment: Foundation Medicine. Stock and Other Ownership Interests: …PURPOSE Promising single-agent activity from sotorasib and adagrasib in KRASG12C-mutant tumors has provided clinical evidence of effective KRAS signaling inhibition. However, comprehensive analysis of KRAS-variant prevalence, genomic alterations, and the relationship between KRAS and immuno-oncology biomarkers is lacking. MATERIALS AND METHODS Retrospective analysis of deidentified records ...

DOI: 10.1200/PO.18.00401 JCO Precision Oncology - published online June 20, 2019 Plasma Cell-Free DNA Testing of Patients With EGFR Mutant Non–Small-Cell Lung Cancer: Droplet Digital PCR Versus Next-Generation Sequencing Compared With Tissue-Based Results

DOI: 10.1200/PO.21.00047 JCO Precision Oncology no. 5 (2021) 808-816. Published online May 12, 2021. PMID: 34994613. Clinical Implications of Pathogenic Germline Variants in Small Intestine Neuroendocrine Tumors (SI-NETs) Kimberly Perez, MD 1, 2. x. Kimberly Perez. Search for articles by this author ...

Jun 27, 2017 · Purpose Multiple-gene, next-generation sequencing panels are increasingly used to assess hereditary cancer risks of patients with diverse personal and family cancer histories. The magnitude of breast and ovarian cancer risk associated with many clinically tested genes, and independent of family cancer history, remains to be quantified. Methods We queried a commercial laboratory database of ... Limit abstract length to 275 words. Limit body text to 3,000 words (excluding the title page, abstract, references, figures, and tables). Limit of 6 total figures and tables, not including figure pieces. Table pieces (such as Table 1a and 1b) are not allowed. Include a CONSORT diagram for studies in which two or more groups are compared. Jan 1, 2020 · JCO PO publishes controlled randomized clinical trials and other comparative studies in precision oncology. For randomized clinical trials and other comparative studies, authors should carefully follow the ICMJE and CONSORT statement guidelines. To produce consistent results, please refer to JCO PO 's CONSORT template. DOI: 10.1200/PO.22.00715 JCO Precision Oncology no. 7 (2023) e2200715. Published online June 7, 2023. PMID: 37285561. Comprehensive Review on the Clinical Impact of Next-Generation Sequencing Tests for the Management of Advanced Cancer Sarah N. Gibbs, MPH 1. x. Sarah N. Gibbs. Search for articles by this author ...WebOncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic mutations and structural alterations present in patient tumors with …WebThis author is an Associate Editor for JCO Precision Oncology. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Ciitizen Corporation, Clariifi, Guidance Genomics. Consulting or Advisory Role: Roche, Roche/Genentech. Speakers' Bureau: GenentechJCO Precision Oncology Conversations is a monthly podcast featuring conversations with authors of clinically relevant and significant articles published in the …DOI: 10.1200/PO.18.00414 JCO Precision Oncology no. 4 (2020) 557-569. Published online June 1, 2020. PMID: 32923885. Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients Jingyu Cao, MD 1. x. Jingyu Cao. Search for articles by this author; Jing ...

PURPOSE CATCH (Comprehensive Assessment of clinical feaTures and biomarkers to identify patients with advanced or metastatic breast Cancer for marker driven trials in Humans) is a prospective precision oncology program that uses genomics and transcriptomics to guide therapeutic decisions in the clinical management of metastatic breast cancer. Herein, we report our single-center experience and ...DOI: 10.1200/PO.22.00107 JCO Precision Oncology no. 6 (2022) e2200107. Published online August 17, 2022. PMID: 35977349. Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors Matthew Dankner, BSc 1, 2, 3. x. Matthew Dankner. Search for articles by this …PURPOSE The STAMPEDE trial recruits men with newly diagnosed, high-risk, hormone-sensitive prostate cancer. To ascertain the feasibility of targeted next-generation sequencing (tNGS) and the prevalence of baseline genomic aberrations, we sequenced tumor and germline DNA from patients with metastatic prostate cancer (mPCa) starting long-term androgen-deprivation therapy (ADT). METHODS In a 2 ...Instagram:https://instagram. best real estate etfshow many home loans can you havestock trading schoolsinverted yield curve meaning 31 Aug 2022 ... Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): an MD Anderson Precision Medicine Study. JCO Precis. Oncol. 2017;2017. .telsafely short term rental insurance Jan 14, 2021 · DOI: 10.1200/PO.20.00250 JCO Precision Oncology no. 5 (2021) 204-214. Published online January 14, 2021. Published online January 14, 2021. NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome target date funds vs sandp 500 DOI: 10.1200/PO.21.00437 JCO Precision Oncology no. 6 (2022) e2100437. Published online January 27, 2022. Published online January 27, 2022. Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature …DOI: 10.1200/PO.21.00245 JCO Precision Oncology no. 6 (2022) e2100245. Published online March 23, 2022. PMID: 35319967. Landscape of KRAS G12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers Mohamed E. Salem, MD 1. x ...Web